Washington Trust Advisors’s Dyne Therapeutics DYN Stock Holding History

Washington Trust Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-125	Closed	-$1.58K	–	613
2025 Q3	$1.58K	Hold	125	–	–	﹤0.01%	671
2025 Q2	$1.19K	Hold	125	–	–	﹤0.01%	622
2025 Q1	$1.31K	Hold	125	–	–	﹤0.01%	618
2024 Q4	$2.94K	Hold	125	–	–	﹤0.01%	601
2024 Q3	$4.49K	Hold	125	–	–	﹤0.01%	589
2024 Q2	$4.41K	Hold	125	–	–	﹤0.01%	582
2024 Q1	$3.55K	Hold	125	–	–	﹤0.01%	608
2023 Q4	$1.66K	Hold	125	–	–	﹤0.01%	648
2023 Q3	$1.12K	Hold	125	–	–	﹤0.01%	661
2023 Q2	$1.41K	Hold	125	–	–	﹤0.01%	640
2023 Q1	$1.44K	Hold	125	–	–	﹤0.01%	747
2022 Q4	$1.45K	Hold	125	–	–	﹤0.01%	747
2022 Q3	$2K	Buy	+125	New	+$1.43K	﹤0.01%	848
2022 Q1	–	Sell	-63	Closed	-$1K	–	1003
2021 Q4	$1K	Buy	+63	New	+$885	﹤0.01%	981

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Washington Trust Advisors's DYN Position: Q4 2025 in Review

Washington Trust Advisors sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 125 shares — an estimated $1.58K sold.

Washington Trust Advisors first reported a position in DYN in Q4 2021 and held it in 14 quarters. The position peaked at $4.49K in Q3 2024. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

Washington Trust Advisors reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
Washington Trust Advisors sold 125 Dyne Therapeutics shares in Q4 2025, an estimated $1.58K.
Washington Trust Advisors first reported a position in Dyne Therapeutics in Q4 2021 and held it in 14 quarters.
Washington Trust Advisors's Dyne Therapeutics position peaked at $4.49K in Q3 2024.
232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.